Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5219439
Max Phase: Preclinical
Molecular Formula: C84H111N19O26S
Molecular Weight: 1834.99
Associated Items:
ID: ALA5219439
Max Phase: Preclinical
Molecular Formula: C84H111N19O26S
Molecular Weight: 1834.99
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)COCCOCCNC(=S)Nc1ccc2c(c1)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H]1CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCC(N)=O)NC1=O)C(C)C
Standard InChI: InChI=1S/C84H111N19O26S/c1-41(2)67(101-74(118)54(17-11-27-89-82(87)88)95-77(121)59(39-104)93-64(108)40-127-32-31-126-30-28-90-83(130)92-45-19-22-49-48(34-45)81(125)129-84(49)50-23-20-46(105)35-61(50)128-62-36-47(106)21-24-51(62)84)79(123)102-68(42(3)4)80(124)103-29-12-18-60(103)78(122)97-53-16-10-9-15-52(72(116)100-58(38-66(111)112)75(119)91-43(5)70(114)98-56(69(86)113)37-65(109)110)94-76(120)57(33-44-13-7-6-8-14-44)99-73(117)55(96-71(53)115)25-26-63(85)107/h6-8,13-14,19-24,34-36,41-43,52-60,67-68,104-106H,9-12,15-18,25-33,37-40H2,1-5H3,(H2,85,107)(H2,86,113)(H,91,119)(H,93,108)(H,94,120)(H,95,121)(H,96,115)(H,97,122)(H,98,114)(H,99,117)(H,100,116)(H,101,118)(H,102,123)(H,109,110)(H,111,112)(H4,87,88,89)(H2,90,92,130)/t43-,52-,53-,54-,55-,56-,57-,58-,59-,60-,67-,68-/m0/s1
Standard InChI Key: NXOOQBFFDXRNCK-MURMVRIRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1834.99 | Molecular Weight (Monoisotopic): 1833.7668 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Krzyzanowski A, Esser LM, Willaume A, Prudent R, Peter C, 't Hart P, Waldmann H.. (2022) Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors., 65 (22.0): [PMID:36378254] [10.1021/acs.jmedchem.2c01273] |
Source(1):